STONEBRANCH
9.4.2024 15:01:34 CEST | Business Wire | Press release
Stonebranch, a leading provider of service orchestration and automation solutions, today published the 2024 Global State of IT Automation Report: IT Automation and Orchestration Benchmarks for IT Ops, DevOps, CloudOps, and DataOps Teams, its third-annual benchmark study on the automation priorities, expectations, and challenges of IT professionals worldwide.
“We're pleased to release our Global State of IT Automation Report, now in its third year,” said Giuseppe Damiani, Stonebranch CEO. “This research offers a detailed analysis of current trends, challenges, and opportunities in IT automation and orchestration, providing valuable benchmarks for IT professionals worldwide. We're passionate about contributing to the IT industry's evolution and innovation, and we're dedicated to helping our customers realize their automation potential.”
Key Insights from the 2024 Global State of IT Automation Report
The 2024 Global State of IT Automation Report is based on a survey of IT automation professionals and executives, conducted by Censuswide between January 24 – February 5, 2024.
This year's report unveils critical insights into the evolving landscape of IT automation, offering a unique lens through which IT Ops, DevOps, CloudOps, and DataOps professionals can view the future of automation and orchestration technologies. Three notable emerging trends include:
- Automation is Evolving into Orchestration: Driven by a desire to orchestrate across complex hybrid IT environments, 82% of respondents plan to replace legacy IT automation tools or add new automation tools to the mix.
- Democratization of Automation Continues to Grow: 88% of respondents enable end-users across the business with self-service access to IT automation. Those who plan to add or replace IT automation tools with a more modern solution cited a desire to add self-service as the leading reason for change.
- Companies Prefer a Mix of On-Prem and Cloud Environments: In only one year, hybrid IT usage has doubled from 34% to 68%. Organizations are deciding where to store data — either on-prem or cloud — on a case-by-case basis. This approach is efficient and flexible but poses a challenge when it comes to automating and orchestrating these environments.
- Machine Learning Pipelines are Evolving and Growing in Importance: A significant 74% of respondents have already incorporated data and ML pipelines to operationalize their AI-driven initiatives. This is an indicator of many companies’ strong commitment to the pivotal role of AI in shaping their future success.
Peter Baljet, Stonebranch CTO, notes, “Our findings show that companies are adapting their IT automation and orchestration strategies to meet the specific challenges that come with cloud technologies. In the complex world of today’s hybrid IT environments, automation is crucial to enhance performance, secure systems, and control costs.”
To fully explore the research results:
- Download the full report — Stonebranch 2024 Global State of IT Automation: IT Automation and Orchestration Benchmarks for IT Ops, DevOps, CloudOps, and DataOps Teams.
- Watch the research results webinar, which highlights key trends and insights from the report, as well as Stonebranch’s recommendations for success.
About Stonebranch
Stonebranch builds IT orchestration and automation solutions that transform business IT environments from simple IT task automation into sophisticated, real-time business service automation. No matter the degree of automation, the Stonebranch platform is simple, modern, and secure. Using the Stonebranch Universal Automation Center platform, enterprises can seamlessly orchestrate workloads and data across technology ecosystems and silos. Headquartered in Atlanta, Georgia, with points of contact and support throughout the Americas, Europe, and Asia, Stonebranch serves some of the world’s largest financial, manufacturing, healthcare, travel, transportation, energy, and technology institutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409835235/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom